Fighting Cancer with Next-Gen Cell Engineering

DR. FRANCIS COLLINS | July 11, 2019

article image
Researchers continue to make progress with cancer immunotherapy, a type of treatment that harnesses the bodys own immune cells to attack cancer. But Kole Roybal wants to help move the field further ahead by engineering patients’ immune cells to detect an even broader range of cancers and then launch customized attacks against them. With an eye toward developing the next generation of cell-based immunotherapies, this synthetic biologist at University of California, San Francisco, has already innovatively hacked into how certain cells communicate with each other. Now, he and his research team are using a 2018 NIH Director’s New Innovator Award to build upon that progress.

Spotlight

Xell AG

Xell is an experienced partner for companies in the biotech and pharmaceutical industry providing them with highly-efficient solutions in cell culture technology. Meeting our customers’ specific needs is the objective of our dedicated team – our personal approach to challenging tasks is key to Xell’s success. With years of industry experience, we bring our extensive expertise in ultra-high performance media and feed development, and apply our powerful analytical tools for in-depth characterization of biological systems and pharmaceutical proteins, guaranteeing optimal solutions for our customers’ bioprocesses.

OTHER ARTICLES
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
DIAGNOSTICS

Making Predictions by Digitizing Bioprocessing

Article | April 20, 2021

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Spotlight

Xell AG

Xell is an experienced partner for companies in the biotech and pharmaceutical industry providing them with highly-efficient solutions in cell culture technology. Meeting our customers’ specific needs is the objective of our dedicated team – our personal approach to challenging tasks is key to Xell’s success. With years of industry experience, we bring our extensive expertise in ultra-high performance media and feed development, and apply our powerful analytical tools for in-depth characterization of biological systems and pharmaceutical proteins, guaranteeing optimal solutions for our customers’ bioprocesses.

Events